<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790734</url>
  </required_header>
  <id_info>
    <org_study_id>WUHICU202101</org_study_id>
    <nct_id>NCT04790734</nct_id>
  </id_info>
  <brief_title>Remimazolam Besylate in Mechanically Ventilated ICU Patients</brief_title>
  <official_title>Efficacy and Safety of Remimazolam Versus Propofol for Sedation in Mechanically Ventilated ICU Patients: a Randomized, Open-label, Small Sample Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of remimazolam compared to&#xD;
      propofol for sedation in mechanically ventilated ICU patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, small sample study using remimazolam and propofol for&#xD;
      sedation in mechanically ventilated ICU patients. Subjects are randomized to different&#xD;
      treatment groups (including 1 for Remimazolam Besylate and 1 for propofol). Remifentanil is&#xD;
      co-administered with remimazolam or propofol. Efficacy and safety profiles of Remimazolam&#xD;
      Besylate are to be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive ventilator free time within 7 days</measure>
    <time_frame>Within 7 days of the study began</time_frame>
    <description>The time without invasive ventilation within 7 days of the study began</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of no other sedative drugs or muscle relaxants use within 7 days</measure>
    <time_frame>Within 7 days of the study began</time_frame>
    <description>The proportion of participants who did not use other sedative drugs or muscle relaxants within 7 days of the study began (except for short-term use such as induction of tracheal intubation or tracheotomy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-ICU survival time within 7 days</measure>
    <time_frame>Within 7 days of the study began</time_frame>
    <description>The time of survival outside of ICU within 7 days of the study began</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of successful extubation within 7 days</measure>
    <time_frame>Within 7 days of the study began</time_frame>
    <description>The proportion of participants who experienced successful extubation within 7 days of the study began</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Case fatality rate within 28 days</measure>
    <time_frame>Within 28 days of the study began</time_frame>
    <description>After follow-up, the fatality rates of all enrolled patients (including those still in ICU, transferred out and discharge) within 28 days of the study began</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive ventilator free time in the ICU within 28 days</measure>
    <time_frame>Within 28 days of the study began</time_frame>
    <description>The time without invasive ventilation in the ICU within 28 days of the study began</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Remimazolam Besylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remimazolam continuous infusion of 0.1 to 0.2 mg/kg/h to reach a RASS score of -3 to 0.&#xD;
remifentanil continuous infusion of 4 to 9 ug/kg/h to reach a CPOT score of 0 to 2.&#xD;
The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol continuous infusion of 0.5 to 4 mg/kg/h to reach a RASS score of -3 to 0.&#xD;
remifentanil continuous infusion of 4 to 9 ug/kg/h to reach a CPOT score of 0 to 2.&#xD;
The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam Besylate</intervention_name>
    <description>To achieve light/moderate sedation.</description>
    <arm_group_label>Remimazolam Besylate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>To achieve light/moderate sedation.</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>remifentanil</description>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_label>Remimazolam Besylate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged &gt;= 18 and &lt;= 75 years;&#xD;
&#xD;
          -  Endotracheal intubated;&#xD;
&#xD;
          -  Patients expected to be mechanically ventilated &gt;= 24h;&#xD;
&#xD;
          -  Demand for light/moderate sedation (a RASS score of -3 to 0).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant;&#xD;
&#xD;
          -  Lactant;&#xD;
&#xD;
          -  Severe central nervous system disease (massive cerebral infarction/hemorrhage; status&#xD;
             epilepticus; severe dementia, etc.);&#xD;
&#xD;
          -  Acute hepatitis;&#xD;
&#xD;
          -  Severe liver disease (Child-Pugh C);&#xD;
&#xD;
          -  Chronic kidney disease (CKD grade 3 above);&#xD;
&#xD;
          -  Unstable angina pectoris or acute myocardial infarction;&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;= 30%;&#xD;
&#xD;
          -  Heart rate &lt; 50bpm;&#xD;
&#xD;
          -  Type 2 second-degree or third-degree atrioventricular block (except those implanted a&#xD;
             pacemaker);&#xD;
&#xD;
          -  Two vasoconstrictors are used to maintain SBP above 90mmHg after sufficient fluid&#xD;
             resuscitation;&#xD;
&#xD;
          -  Acute glaucoma&#xD;
&#xD;
          -  Myasthenia gravis;&#xD;
&#xD;
          -  Alcohol or drug withdrawa;&#xD;
&#xD;
          -  Psychopath&#xD;
&#xD;
          -  Near death;&#xD;
&#xD;
          -  Allergic to remimazolam, propofol, benzodiazepines or its excipients (lactose/dextrin&#xD;
             40); lipid emulsion; or other diseases (such as pancreatitis associated with&#xD;
             hyperlipidemia) for which lipid emulsion should not be used;&#xD;
&#xD;
          -  Informed Consent is unsigned.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>You Shang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICU, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaobo Yang, MD</last_name>
    <phone>13720311349</phone>
    <email>want.tofly@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>You Shang, Professor</last_name>
    <email>you_shanghust@163.com</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>remimazolam besylate</keyword>
  <keyword>propofol</keyword>
  <keyword>Intensive care unit</keyword>
  <keyword>Mechanical ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

